US OptionsDetailed Quotes
NMRA241220C2500
- 0.00
- 0.000.00%
15min DelayClose Dec 20 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover0.00%IV-76.96%PremiumDec 20, 2024Expiry Date8.35Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.30Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Neumora Therapeutics Stock Discussion
Sign in to post a comment
The market fell Monday, but $NVIDIA (NVDA.US)$ and $Apple (AAPL.US)$ hit all-time highs. Investors will see some heavy hitter earnings this week, including Tesla on Wednesday, where investors will judge the EV firm's Q3 results.
Just after 4 pm, the $S&P 500 Index (.SPX.US)$ fell 18 basis points, the $Dow Inc (DOW.US)$ fell 0.80%, and the $Nasdaq Composite Index (.IXIC.US)$ climbed 0.27% on tech positivity.
MACRO
This...
Just after 4 pm, the $S&P 500 Index (.SPX.US)$ fell 18 basis points, the $Dow Inc (DOW.US)$ fell 0.80%, and the $Nasdaq Composite Index (.IXIC.US)$ climbed 0.27% on tech positivity.
MACRO
This...
54
17
12
Good afternoon traders, happy Monday, October 21st, the start of a brand new week! Investors will see some heavy hitter earnings this week, including the first of the magnificent seven, Tesla reporting on Wednesday. The market is falling Monday, after hitting highs Thursday last week.
My name is Kevin Travers; here are the news stories and animal spirits hitting Wall Street Today.
$Spirit Airlines (SAVE.US)$ jumped more th...
My name is Kevin Travers; here are the news stories and animal spirits hitting Wall Street Today.
$Spirit Airlines (SAVE.US)$ jumped more th...
34
26
1
Ms. Pai Panandiker's appointment, with her vast neuropsychiatry commercial expertise, is seen as invaluable for Neumora's potential commercialization of navacaprant and pipeline advancement. Her experience in neuroscience product commercialization is expected to boost Neumora's growth.
1
CEO of Neumora Therapeutics is optimistic over Mr. Duncan's appointment due to his legal expertise and program strategy, valuable to the company's goal of advancing neuroscience drug development. Duncan highlights Neumora's leading brain disorder pipeline and recent clinical progress.
CEO of Neumora, Henry Gosebruch, values Dr. Lenz's successful trial experience and neuroscience expertise for their pipeline development. Dr. Lenz is excited to contribute significantly to Neumora's R&D and neuropsychiatry programs.
$Axcella Health (AXLA.US)$ Ranked #1 by Fintel. Its next run should take it to about 14.90.
$Ontrak (OTRK.US)$ Has been out of shares for a week. Small float and cheap price. Can run as high as 2.94 when it finally does get volume.
$Neumora Therapeutics (NMRA.US)$ Recent IPO and has been steady moving up from its low of 9.80. Now comes the bigger gap ups . 17.74 is its breakout.
$Prestige Wealth (PWM.US)$ Seems to have found bottom at 3.10. If it has ER on October 6 that is. S...
$Ontrak (OTRK.US)$ Has been out of shares for a week. Small float and cheap price. Can run as high as 2.94 when it finally does get volume.
$Neumora Therapeutics (NMRA.US)$ Recent IPO and has been steady moving up from its low of 9.80. Now comes the bigger gap ups . 17.74 is its breakout.
$Prestige Wealth (PWM.US)$ Seems to have found bottom at 3.10. If it has ER on October 6 that is. S...
7
9
McHTP
1
$Neumora Therapeutics (NMRA.US)$ red already!
No comment yet
104247826 :![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Adrianlim90 : 1
enfath2022 :![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Chak : Because of this bastard Bank Of America, this news was hidden by CNBC. It was not on the main page and everybody wondering why it is popping up. It popped up three dollars today.Bank of America hikes Nvidia price target, says shares can rally almost 40%
102188459 : Yq
View more comments...